Lung Cancer Dispatch
Follow
Find tag "NHS"
3.8K views | +2 today
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

NICE to Bar Second-Line Use of Tarceva

NICE to Bar Second-Line Use of Tarceva | Lung Cancer Dispatch | Scoop.it

"A proposal by (National Health Service) NHS cost regulators to no longer back the second-line use of Tarceva (erlotinib) to treat relapsed non-small cell lung cancer (NSCLC) has angered the drug's manufacturer Roche and will no doubt come as a shock to patients.


"Following a review of existing guidance, the National Institute for Health and Care Excellence (NICE) has decided that treatment with Tarceva after first-line therapy has failed is no longer a cost-effective option for the NHS.

 

"According to Roche, the move means that more than 1,000 patients in England and Wales every year will be at risk from being left without an active second-line treatment option."

Cancer Commons's insight:

PharmaTimes  |  Feb 4, 2014

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

UK Health Authority Releases List of Recommended Tests for EGFR Mutation

UK Health Authority Releases List of Recommended Tests for EGFR Mutation | Lung Cancer Dispatch | Scoop.it

The UK's National Institute for Health and Clinical Excellence (NICE) has released a guidance document specifying which tests it recommends for detecting mutations of the EGFR gene in non-small cell lung cancer (NSCLC) patients. Patients with EGFR mutations usually benefit more from treatment with EGFR inhibitors rather than traditional chemotherapy, while these drugs are less effective in patients without such mutations. Accurate detection of EGFR mutations is therefore very important. NICE recommends the therascreen EGFR RGQ PCR Kit, the cobas EGFR mutation test, Sanger sequencing of samples, or combined approaches that use Sanger sequencing for samples with more than 30% tumor cells, and one of the two other tests for samples with lower tumor cell density.

Cancer Commons's insight:

National Institute for Health and Care Excellence | Aug 13, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

UK Health Authority Issues Final Rejection for Cancer Drug Xalkori

UK Health Authority Issues Final Rejection for Cancer Drug Xalkori | Lung Cancer Dispatch | Scoop.it

The UK’s National Institute for Health and Clinical Excellence (NICE) confirmed its decision to reject using National Health Service funding to provide crizotinib (Xalkori) to patients. Xalkori is used for patients with previously treated non-small cell lung cancer (NSCLC) who have mutations in the ALK gene. While NICE acknowledges that Xalkori is effective in these patients, they do not consider its benefit substantial enough to warrant its high cost. Xalkori has been found to extend the time without cancer progression by an average of 5.1 months compared to standard chemotherapy; it is unclear whether it increases overall survival. UK patients can still take Xalkori, but would have to pay the full cost themselves (£37,512 - £51,579 for a complete treatment course).

Cancer Commons's insight:

PharmaTimes | Sep 25, 2013

more...
Raja Mudad's curator insight, September 27, 2013 9:31 AM

We are very lucky in this country (so far!!) to be able to use cutting edge, science-based treatments for cancers.  Xalkori (crizotinib) for ALK + patients with lung cancer will not be covered in the UK.

Suggested by Cancer Commons
Scoop.it!

UK Health Authority Provisionally Rejects Funding for Cancer Drug Xalkori

UK Health Authority Provisionally Rejects Funding for Cancer Drug Xalkori | Lung Cancer Dispatch | Scoop.it

The UK’s National Institute for Health and Clinical Excellence (NICE) has provisionally recommended against the use of National Health Service resources to provide crizotinib (Xalkori) to patients. NICE considers the drug to be too expensive for the expected benefit. Xalkori is used to treat patients with previously treated non-small cell lung cancer (NSCLC) who have mutations in the ALK gene. The drug has been approved in the U.S. since August, 2011, and conditionally approved in Europe since October, 2012. Patients in the UK can still get access to Xalkori, but would have to cover the cost (£4,689/$7,100 for a 30-day supply) themselves. NICE’s provisional guidance is up for comment, after which a second draft guidance will be issued. More details at: http://www.pharmatimes.com/Article/13-03-27/NICE_issues_draft_no_for_Pfizer_s_Xalkori_but_opens_consultation.aspx

Cancer Commons's insight:

PMLiVE  | Mar 27, 2013

more...
No comment yet.